Leap Therapeutics Inc (LPTX) Opciones

And some more 3,25's longterm, ANT

added 3,70 ANT

held first support, startin' to like this one more and more, gild support, fyi ANT

added first support, ANT

consistent buyin' often means deeper pockets like what they see or are about to find out, so they add while it's cheap, imo but we'll see soon, ANT

puppy's goin' for a new 52wk high imo ANT

because it's a double digitland stock, xcellent results will propel it imosho ANT

Any clue what's driving this major upside move the last week?

LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX under $3

LPTX under $3

LPTX under $2

LPTX under $5

LPTX...................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX 10Q due March 12

LPTX.......................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX new 52 week low

LPTX new 52 week low

Wow..almost a year and no one posted anything!!

No one in their right mind gives 2 Sheets what some joke analyst gives for any price target

They are Shills

LPTX Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update Jan. 23
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics (LPTX) to $6 from $5 and keeps an Overweight rating on the shares. Following the ASCO GI update for DKN-01, Leap hosted a conference call on Friday to walk through the data and lay out potential next steps, the analyst notes. When considering potential treatment effect, Catanzaro thinks the signal in DKK1-high patients looks even more compelling. Leap believes it could initiate a small randomized Phase II as part of the current IND that could generate data in 2023, while simultaneously engaging regulatory agencies on registrational strategies. Most notably, BeiGene's (BGNE) opt-in decision for Asian rights will almost certainly be a 2022 event, and the analyst continues to believe the ASCO GI update should make that a straightforward choice.

yep, something big happening here.

4.08 > hod.

I think I am going to double my position on Monday

Yeah that was super strong after share offer . I think Beigene (sp?) may know this is real and we are a $10 acquisition target next year

The daily build up of short exempts on this momentum is driving the move. The cancer treatment results started the move. We shook off the share dump like it was nothing

Yes unbelievable dude . Cancer tests must be solid behind the scenes too

I got to tell you we are holding better then I thought. This may squeeze soon

yes, oddly. watch for a pull back.

Premarket looks good

yeah it's going to linger for a month now. But once Beigeine exercises their old warrants it's a good sign.

Share options were executed for $2.77 up to 15% of OS. DILUTION!!!! See what happens. This timing couldn't be any worse.

Yes agreed never understood this . They use great news to create more liquidity for them and long term usually good but be better if the price was $5-$10 not $3. By they way offering price says $2.75-2.85 on Td Ameritrade but can’t locate the Amount of shares yet .

The only reason I ask is LPTX has a beautiful setup right now with MMs providing buying pressure through building daily short exempts. Not to mention I added a big chuck to my position today. I hate when this happens because while the company is able to raise cash it kills momentum

The offering? Didnt have time to research . Maybe in filing tomorrow?

How many shares do you think that was?

Yeah hate when they dilute, but long term it means big interest so we will see new highs again in a few
Months

That was BS at close!!!!

Been sitting on tons of shares for 6 months. Bought most at $2.10 range. This can go much higher.

Just added 4000 shares! Let's go

Well it's ripping. Lol

Let her rip next week fellows

Yes it’s our time

$2.50 pre-market

This with good results is a $10 stock.

hod $1.95 nice

Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress
6:00 am ET September 13, 2021 (PR Newswire) Print
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, being held virtually on September 16-21, 2021. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from the study.

"Initial data from the DisTinGuish study is extremely promising as it shows DKN-01 in combination with tislelizumab and chemotherapy to have high response rates in first-line patients suffering from gastric and gastroesophageal junction cancer," said Cynthia Sirard, MD, Chief Medical Officer of Leap. "Patients whose tumors have high levels of DKK1 expression, which is known to correlate with aggressive disease and poor prognosis, showed the highest response rates, suggesting how important the biomarker may be in predicting response to therapy. Additional data will be presented at ESMO and in our conference call to demonstrate the potential DKN-01 has as part of first-line therapy in this difficult-to-treat indication."

About the DisTinGuish Study

The DisTinGuish study (NCT04363801) is a Phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. The study is being conducted in two parts, in the United States and the Republic of Korea. Enrollment of Part A has been completed with 25 first-line HER2- G/GEJ cancer patients whose tumors express either high levels of DKK1 (DKK1-high) or low levels of DKK1 (DKK1-low). Part B of the study will enroll up to 48 patients with second-line, DKK1-high G/GEJ cancer. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

Key Findings

-- DKN-01 in combination with tislelizumab and chemotherapy demonstrated compelling overall response rates (ORR) as a first-line treatment for advanced G/GEJ cancer

-- In the primary efficacy analysis, including all patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in DKK1-high patients as compared to a 56% ORR in DKK1-low patients

-- In the overall intent to treat population, including those patients who did not receive a full cycle of therapy, the ORR was 60%, with 75% ORR in DKK1-high patients as compared to a 56% ORR in DKK1-low patients

As of the date of the abstract, 13 patients had experienced a partial response (PR), six patients had a best response of stable disease (SD), one patient was non-evaluable for response (NE), three patients were unable to complete a full cycle of therapy (non-modified ITT (mITT)), and two patients were pending their first tumor assessment. Of the 18 patients that had RNAscope(R) DKK1 expression available for the abstract, 9 were DKK1-high [6 PR, 1 NE, and 2 non-mITT] and 9 were DKK1-low [5 PR, 4 SD]. Subsequent to the date of the abstract, the two patients who were pending their first scan for response to therapy were determined to have had PRs, and three additional patients were determined to have had DKK1-high tumors, each of whom experienced a PR.

Further results will be presented at the ESMO 2021 Congress from September 16 to 21, 2021.

Leap Presentation Details:

Title: DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial Abstract Number: 2218Session type: E-Poster PresentationPresenter: Samuel J. Klempner, Harvard Medical SchoolDate and time: Thursday, September 16, 2021; 2:30 a.m. ET

Conference Call

Leap will host a conference call on Friday, September 17, 2021 at 8:00 a.m. Eastern Time to further discuss the data. In addition to Leap's executive management team, Dr Jaffer Ajani of M.D. Anderson Cancer Center and Dr. Samuel Klempner of Massachusetts General Hospital will be on the call. The call can be accessed by dialing (866) 589-0108 (U.S. and Canada) or (409) 231-2048 (international). The passcode for the conference call is 1729397. The presentation will be webcast live and may be accessed on the Investors page of the Company's website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

RNAscope(R) is a registered trademark of Advanced Cell Diagnostics, Inc., Newark, CA, USA.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 12, 2021 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Dkn01 + paclitaxel -Bristol
Dkn01 + opdivo - Bristol
Dkn01 + keytruda - Merck
Dkn01 + tislezimub- beigen
Dkn01 + docetaxel - Pfizer
Dkn01 + atezelimubab - roche
Dkn01 + sorenifib - BAYER/onyx